These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 27495951)
1. Histopathological and ophthalmoscopic evaluation of apocynin on experimental proliferative vitreoretinopathy in rabbit eyes. Ozer MA; Polat N; Ozen S; Ogurel T; Parlakpinar H; Vardi N Int Ophthalmol; 2017 Jun; 37(3):599-605. PubMed ID: 27495951 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of experimental proliferative vitreoretinopathy in rabbits by suramin. de Souza OF; Sakamoto T; Kimura H; Koda RP; Gabrielian K; Spee C; Ryan SJ Ophthalmologica; 1995; 209(4):212-6. PubMed ID: 8545096 [TBL] [Abstract][Full Text] [Related]
3. The effect of tranilast on experimental proliferative vitreoretinopathy. Ito S; Sakamoto T; Tahara Y; Goto Y; Akazawa K; Ishibashi T; Inomata H Graefes Arch Clin Exp Ophthalmol; 1999 Aug; 237(8):691-6. PubMed ID: 10459620 [TBL] [Abstract][Full Text] [Related]
4. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy. Mandava N; Blackburn P; Paul DB; Wilson MW; Read SB; Alspaugh E; Tritz R; Barber JR; Robbins JM; Kruse CA Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3338-48. PubMed ID: 12356843 [TBL] [Abstract][Full Text] [Related]
5. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. Ozerdem U; Mach-Hofacre B; Cheng L; Chaidhawangul S; Keefe K; McDermott CD; Bergeron-Lynn G; Appelt K; Freeman WR Curr Eye Res; 2000 Jun; 20(6):447-53. PubMed ID: 10980656 [TBL] [Abstract][Full Text] [Related]
6. [Role of Chlamydia trachomatis intraocular infection in the development of proliferative vitreoretinopathy (experimental study)]. Boiko EV; Pozniak AL; Suetov AA; Mal'tsev DS; Nuralova IV Vestn Oftalmol; 2015; 131(1):50-57. PubMed ID: 25872387 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of experimental proliferative vitreoretinopathy by retroviral vector-mediated transfer of suicide gene. Can proliferative vitreoretinopathy be a target of gene therapy? Sakamoto T; Kimura H; Scuric Z; Spee C; Gordon EM; Hinton DR; Anderson WF; Ryan SJ Ophthalmology; 1995 Oct; 102(10):1417-24. PubMed ID: 9097787 [TBL] [Abstract][Full Text] [Related]
9. Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy. Szczesniak AM; Porter RF; Toguri JT; Borowska-Fielding J; Gebremeskel S; Siwakoti A; Johnston B; Lehmann C; Kelly ME Neuropharmacology; 2017 Feb; 113(Pt B):627-638. PubMed ID: 27569993 [TBL] [Abstract][Full Text] [Related]
10. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy. Ozerdem U; Mach-Hofacre B; Keefe K; Pham T; Soules K; Appelt K; Freeman WR Ophthalmic Res; 2001; 33(1):20-3. PubMed ID: 11114600 [TBL] [Abstract][Full Text] [Related]
11. SU9518 inhibits proliferative vitreoretinopathy in fibroblast and genetically modified Müller cell-induced rabbit models. Velez G; Weingarden AR; Lei H; Kazlauskas A; Gao G Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1392-7. PubMed ID: 23341018 [TBL] [Abstract][Full Text] [Related]
12. An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. Cardillo JA; Farah ME; Mitre J; Morales PH; Costa RA; Melo LA; Kuppermann B; Jorge R; Ashton P Br J Ophthalmol; 2004 Sep; 88(9):1201-5. PubMed ID: 15317716 [TBL] [Abstract][Full Text] [Related]
13. A sustained dual drug delivery system for proliferative vitreoretinopathy. Xiao Y; Choi KS; Warther D; Huffman K; Landeros S; Freeman WR; Sailor MJ; Cheng L Drug Deliv; 2020 Dec; 27(1):1461-1473. PubMed ID: 33100053 [TBL] [Abstract][Full Text] [Related]
14. Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one. Tikhonovich MV; Erdiakov AK; Gavrilova SA Int Ophthalmol; 2018 Aug; 38(4):1365-1378. PubMed ID: 28639085 [TBL] [Abstract][Full Text] [Related]
17. The Effects of Ozurdex® (Dexamethasone Intravitreal Implant) on Experimental Proliferative Vitreoretinopathy. Kuo HK; Chen YH; Wu PC; Kuo YH Ophthalmologica; 2015; 233(3-4):198-203. PubMed ID: 25721986 [TBL] [Abstract][Full Text] [Related]
18. Use of caffeic acid phenethyl ester and cortisone may prevent proliferative vitreoretinopathy. Turkoz Y; Er H; Borazan M; Yilmaz H; Mizrak B; Parlakpinar H; Cigremis Y Mediators Inflamm; 2004 Apr; 13(2):127-30. PubMed ID: 15203555 [TBL] [Abstract][Full Text] [Related]
19. A new model of proliferative vitreoretinopathy. Frenzel EM; Neely KA; Walsh AW; Cameron JD; Gregerson DS Invest Ophthalmol Vis Sci; 1998 Oct; 39(11):2157-64. PubMed ID: 9761295 [TBL] [Abstract][Full Text] [Related]
20. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy. Nakagawa M; Refojo MF; Marin JF; Doi M; Tolentino FI Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2388-95. PubMed ID: 7591628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]